18 January 2017 - HAS has posted the agenda for the next scheduled TC meeting.

The Transparency Commission will consider the reimbursement of:

• Lenalidomide (Revlimid)
  
• Tenofovir disoproxil fumarate with emtricitabine
  
• Pembrolizumab (Keytruda)
  
• Afatinib dimaleate (Giotrif)
  
• Methyl aminolevulinate hydrochloride (Metvixia)
  

Read TC agenda [French]